Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

Archives of Virology

Volumn 148, Issue 4, 2003, Pages 813-825

  Takakuwa, H ^a   Goshima, F ^a   Nozawa, N ^a   Yoshikawa, T ^a   Kimata, H ^a   Nakao, A ^a   Nawa, A ^b   Kurata, T ^c   Sata, T ^c   Nishiyama, Yukihiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BASE SEQUENCE; CLONE CELLS; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; FIBROSARCOMA; GENE DELETION; HERPESVIRUS 1, HUMAN; IMMUNOCOMPETENCE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PERITONEAL NEOPLASMS; RECOMBINATION, GENETIC; RESTRICTION MAPPING; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

ANIMALIA; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0037388153     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-002-0944-x     Document Type: Article

References (40)

1. Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ (1999) Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 59: 2055-2058
2. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502-1509
3. Becker Y, Hardar J, Tabor E, Ben-Hur T, Raibstein I, Rosen A, Darai G (1986) A sequence in HpaI-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice. Virology 149: 255-259
4. Berkowitz C, Moyal M, Rosen-Wölff A, Darai G, Becker Y (1994) Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice. Arch Virol 134: 73-83
5. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54: 5745-5751
6. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA (1994) Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1: 323-331
7. Carew J, Kooby D, Halterman M, Federoff H, Fong Y (1999) Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10: 1599-1606
8. Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL (1999) Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6: 1751-1758
9. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334
10. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM, Molnar-Kimber KL (1999) Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537
11. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL (2000) Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 7: 275-283
12. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552
13. Fernandez M, Porosnicu M, Markovic D, Bander GN (2002) Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 76: 895-904
14. Fu X, Zhang X (2002) Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 62: 2306-2312
15. Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakfield XO (1998) Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5: 809-819
16. Hirt B (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26: 365-369
17. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787
18. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13: 1325-1334
19. Koshizuka T, Goshima F, Takakuwa H, Nozawa N, Daikoku T, Koiwai O, Nishiyama Y (2002) Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 76: 6718-6728
20. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO (1997) Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8: 2057-2068
21. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874
22. Martuza RL (2000) Conditionally replicating herpes vectors for cancer therapy. J Clinical Invest 105: 841-847
23. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y (2000) Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 4: 580-588
24. Meignier B, Martin B, Whitley RJ, Roizman B (1990) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162(2): 313-321
25. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1(9): 938-943
26. Nishiyama Y, Rapp F (1979) Regulation of persistent infection with herpes simplex virus in vitro by hydrocortisone. J Virol 31: 841-844
27. Nishiyama Y, Kimura H, Daikoku T (1991) Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus type 1 and 2. J Virol 56: 4520-4524
28. Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T, Mizuno M, Colosi P, Kurtzman G, Yoshida J (1996) Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther 3: 957-964
29. Oyama M, Ohigashi T, Hoshi M, Nakashima J, Tachibana M, Uemura K, Yazaki T (2000) Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 11: 1683-1693
30. Ribas A, Bui LA, Butterfield LH, Vollmer CM, Jilani SM, Dissette VB, Glasppy JA, McBride WH, Economou JS (1999) Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 19: 1165-1170
31. Ring CJ (2002) Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83: 491-502
32. Rosenthal LJ, Crutchfield DB, Panitz PJ, Clanton DJ (1983) Isolation of human cytomegalovirus DNA from infected cells. Intervirology 19: 113-120
33. Sata T, Kurata T, Aoyama Y, Sakaguchi M, Yamanouchi K, Takeda K (1986) Analysis of viral antigens in giant cells of measles pneumonia by immunoperoxidase method. Virchow Arch A Pathol Anat Histopathol 410: 133-138
34. Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y (2002) Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 9: 356-364
35. Toda M, Rabkin SD, Kojima H, Martuza RL (1999) Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393
36. Umene K, Eto T, Mori R, Takagi Y, Enquist LW (1984) Herpes simplex virus type 1 restriction fragment polymorphism determined using southern hybridization. Arch Virol 80: 275-290
37. Walker JR, Mcgeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10: 2237-2243
38. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y (2001) Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193: 12-21
39. Yamada Y, Kimura H, Morishima T, Daikoku T, Maeno K, Nishiyama Y (1991) The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 164: 1091-1097
40. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK (1998) Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surgery 288: 366-374